A biomimetic nanoplatform boosting efferocytosis via dual-pathway regulation for atherosclerosis therapy and imaging.

Abstract

Atherosclerosis remains a leading contributor to cardiovascular mortality, driven primarily by defective efferocytosis and subsequent inflammatory within vulnerable plaques. Conventional therapeutic approaches often lack the specificity to simultaneously promote clearance of apoptotic cells and modulate pro-inflammatory signaling. In this study, we presented a biomimetic nanoplatform that enhances efferocytosis through dual-pathway regulation. This platform co-delivers phosphatidylserine (PS) to